KRAS and non-small cell lung carcinoma: Although limited clinical activity was ultimately seen with its combination with defactinib in metastatic KRAS G12V NSCLC in the phase II RAMP202 trial [88], efforts to evaluate other avutometinib combinations in KRAS-mutant NSCLC are ongoing (NCT05074810, NCT05375994, NCT02407509).